 | • レポートコード：B-MOR-040709 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：包装 |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、医薬品委託製造の世界市場について調べ、医薬品委託製造の世界規模、市場動向、市場環境、サービスタイプ別（医薬品有効成分（API）の製造、最終製剤（FDF）の開発・製造、二次包装）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、産業バリューチェーン分析、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・医薬品委託製造の世界市場インサイト ・医薬品委託製造の世界市場環境 ・医薬品委託製造の世界市場動向 ・医薬品委託製造の世界市場規模 ・医薬品委託製造の世界市場規模：サービスタイプ別（医薬品有効成分（API）の製造、最終製剤（FDF）の開発・製造、二次包装） ・医薬品委託製造の世界市場：地域別市場規模・分析 ・医薬品委託製造の北米市場規模・予測 ・医薬品委託製造のアメリカ市場規模・予測 ・医薬品委託製造のヨーロッパ市場規模・予測 ・医薬品委託製造のアジア市場規模・予測 ・医薬品委託製造の日本市場規模・予測 ・医薬品委託製造の中国市場規模・予測 ・医薬品委託製造のインド市場規模・予測 ・関連企業情報・競争状況 |
The global pharmaceutical contract manufacturing market was valued at USD 92.314 billion in 2017. This market is expected to reach USD 146.41 billion by 2023, at a CAGR of 8.08% during the forecast period (2018 – 2023).
Owing to the growing demand for generic medicines and biologics, capital-intensive nature of the business, and complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing. Moreover, the pharmaceutical companies have been directing their priorities toward the core areas of competency, and hence, prefer not to dispense available resources, expertise, and technology on formulating the final dose of medicines. The biggest factor driving the growth of CMOs in the pharmaceutical industry is the growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements. However, factors, such as stringent regulations and high logistics costs are restraining the market.
Increasing Investments on R&D to Drive the Market Growth
Greater technological complexity in drug development and greater specificity in disease targets have helped raise average R&D costs, as firms now identify drugs with particular molecular characteristics as opposed to using trial-and-error methods to find compounds that work in some desired way. A major stake of R&D investments, as well as capacity expansions, are likely in the injectable and sterile liquid dose formulations segment. Small biotech firms get access to specialized knowledge and resources, which help them expedite their R&D activities. Thus, CRO/CMOs are able to leverage their expertise, owing to their R&D and complex manufacturing capabilities, to fill the needs of the large generic, big pharmaceutical and biotech companies.
API to Dominate the Market, by Service Type
Due to restructuring of the pharmaceutical industry, API CMOs are expected to witness a strong surge in demand, particularly in the generics sector. Additionally, regulatory developments in the markets would let generic drug companies develop and manufacture products for export, worldwide. However, demand for specialized technologies and improvements in pharmaceutical manufacturing capabilities, could steer some companies to return to sourcing their APIs from suppliers.
Owing to the Hydroelectricity Concerned Activities in the United States, Utility Sector Accounts for the Largest Share
Generic drugs have a huge opportunity of growth for the CMOs of North America. Traditionally, the CMOs of this region are unwilling to take risks about generics that produce low margins. However, as growing prices push more companies to enter into dermatology products, CMOs with semisolid capabilities are benefitting from strong generics demand. These generic drug companies are also turning more toward CMOs with injectable capabilities to overcome shortage, and to address issues relating to offshore supplies. In addition, the development of super generics are leveraging CMOs with niche dosage forms, like transdermal and inhalation technologies. High cost of production is the main factor for the decline in the market in North America, wherein, an increased number of companies are setting up manufacturing facilities in the emerging countries, or operating through contract manufacturing.
Recent Developments
• October 2017: Catalent Inc., had acquired Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services. This acquisition strengthened Catalent’s position as a leader in biologics development and analytical services, manufacturing and finished product supply. Their complementary capabilities and expertise will help customers accelerate biologic drug development programs and bring better treatments to patients, worldwide.
• June 2017: Recipharm, a leading contract development and manufacturing organization (CDMO) and Kancera, a development company focused on cancer therapy, have signed a contract for the development and manufacture of the pharmaceutical candidate, KAND567.
Major Players: CATALENT INC., RECIPHARM AB, JUBILANT LIFE SCIENCES LTD, PATHEON INC., BOEHRINGER INGELHEIM, PFIZER CENTRESOURCE, AENOVA, FAMAR, BAXTER BIOPHARMA SOLUTIONS, AND LONZA, amongst others.
Reasons to Purchase this Report
• Analysis of how the market scenario of pharmaceutical CMO is changing.
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis.
• The security technology, services, and vertical that are expected to dominate the market.
• The regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 months analyst support, along with the Market Estimate sheet (in excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Scope of the Study
1.2 Executive Summary
2. Research Approach and Methodology
2.1 Key Deliverables of the Study
2.2 Study Assumptions
2.3 Analysis Methodology
2.4 Research Phases
3. Market Insights
3.1 Market Overview
3.2 Industry Attractiveness – Porter’s Five Forces Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Consumers
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitute Products or Services
3.2.5 Competitive Rivalry among Existing Competitors
3.3 Industry Value Chain Analysis
3.4 Industry Policies
4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing Outsourcing Volume by Big Pharmaceutical Companies
4.1.2 Expansion in the Service Offering of CMOS
4.1.3 Advent of CDMO Model into the Market
4.1.4 Increasing Investment in R&D
4.2 Market Restraints
4.2.1 Increasing Lead Time and Logistics Costs
4.2.2 Stringent Regulatory Requirements
4.2.3 Capacity Utilization Issues Affecting the Profitability of CMOS
5. Technology Snapshot
5.1 Dosage Formulation Technologies
5.1.1 Abuse-deterrent Formulation Technology
5.1.2 Lipid Martiparticulate (LMP) Technology
5.1.3 Dry Powder Inhalation Technology
5.1.4 Force Control Agent Technology
5.1.5 High-potency Drug Formulation Technology
5.1.6 Fluidized Bed Coating Technology
5.1.7 Form Eze Technology
5.2 Dosage Forms by Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parental
5.2.4 Rectal
5.2.5 Vaginal
5.2.6 Inhaled
5.2.7 Ophthalmic
5.2.8 Otic
6. Global Pharmaceutical Contract Manufacturing Market Segmentation
6.1 By Service Type
6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.2 Finished Dosage Formulation (FDF) Development & Manufacturing
6.1.2.1 Solid Dose Formulation
6.1.2.2 Liquid Dose Formulation
6.1.2.3 Injectable Dose Formulation
6.1.3 Secondary Packaging
6.2 By Region
6.2.1 North America
6.2.1.1 By Service Type
6.2.1.1.1 API
6.2.1.1.2 FDF
6.2.1.1.2.1 Solid Dose Formulation
6.2.1.1.2.2 Semi-solid/Liquid dose formulation
6.2.1.1.2.3 Injectable Dose Formulation
6.2.1.1.3 Packaging
6.2.1.2 By Country
6.2.1.2.1 United States
6.2.1.2.2 Canada
6.2.2 Europe
6.2.2.1 By Service Type
6.2.2.1.1 API
6.2.2.1.2 FDF
6.2.2.1.2.1 Solid Dose Formulation
6.2.2.1.2.2 Semi-solid/Liquid dose formulation
6.2.2.1.2.3 Injectable Dose Formulation
6.2.2.1.3 Packaging
6.2.2.2 By Country
6.2.2.2.1 United Kingdom
6.2.2.2.2 Germany
6.2.2.2.3 France
6.2.2.2.4 Italy
6.2.2.2.5 Others
6.2.3 Asia-Pacific
6.2.3.1 By Service Type
6.2.3.1.1 API
6.2.3.1.2 FDF
6.2.3.1.2.1 Solid Dose Formulation
6.2.3.1.2.2 Semi-solid/Liquid dose formulation
6.2.3.1.2.3 Injectable Dose Formulation
6.2.3.1.3 Packaging
6.2.3.2 By Country
6.2.3.2.1 China
6.2.3.2.2 India
6.2.3.2.3 Japan
6.2.3.2.4 Australia
6.2.3.2.5 Others
6.2.4 Latin America
6.2.4.1 By Service Type
6.2.4.1.1 API
6.2.4.1.2 FDF
6.2.4.1.2.1 Solid Dose Formulation
6.2.4.1.2.2 Semi-solid/Liquid dose formulation
6.2.4.1.2.3 Injectable Dose Formulation
6.2.4.1.3 Packaging
6.2.4.2 By Country
6.2.4.2.1 Brazil
6.2.4.2.2 Mexico
6.2.4.2.3 Argentina
6.2.4.2.4 Others
6.2.5 Middle East & Africa
6.2.5.1 By Service Type
6.2.5.1.1 API
6.2.5.1.2 FDF
6.2.5.1.2.1 Solid Dose Formulation
6.2.5.1.2.2 Semi-solid/Liquid dose formulation
6.2.5.1.2.3 Injectable Dose Formulation
6.2.5.1.3 Packaging
6.2.5.2 By Country
6.2.5.2.1 UAE
6.2.5.2.2 Saudi Arabia
6.2.5.2.3 South Africa
6.2.5.2.4 Nigeria
6.2.5.2.5 Rest of Middle East & Africa
7. Competitive Landscape
8. Competitive Intelligence – Company Profiles
8.1 Catalent Inc.
8.2 Recipharm AB
8.3 Jubilant Life Sciences Ltd
8.4 Patheon Inc.
8.5 Boehringer Ingelheim
8.6 Pfizer Centresource
8.7 Aenova
8.8 Famar
8.9 Baxter Biopharma Solutions
8.10 Lonza
9. Investment Scenario
10. Future of the Global Pharmaceutical Contract Manufacturing Market